Wall Street brokerages forecast that Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) will report sales of $452.37 million for the current quarter, according to Zacks Investment Research. Three analysts have provided estimates for Jazz Pharmaceuticals’ earnings. The lowest sales estimate is $435.50 million and the highest is $461.60 million. Jazz Pharmaceuticals reported sales of $444.61 million during the same quarter last year, which indicates a positive year over year growth rate of 1.7%. The business is scheduled to report its next earnings report on Tuesday, May 14th.
On average, analysts expect that Jazz Pharmaceuticals will report full year sales of $2.03 billion for the current year, with estimates ranging from $1.95 billion to $2.11 billion. For the next year, analysts forecast that the company will report sales of $2.30 billion, with estimates ranging from $2.21 billion to $2.41 billion. Zacks Investment Research’s sales averages are an average based on a survey of research firms that follow Jazz Pharmaceuticals.
Get Jazz Pharmaceuticals alerts:
Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings data on Tuesday, February 26th. The specialty pharmaceutical company reported $3.64 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.66 by $0.98. The company had revenue of $476.46 million for the quarter, compared to analyst estimates of $459.48 million. Jazz Pharmaceuticals had a net margin of 28.09% and a return on equity of 24.92%. The business’s quarterly revenue was up 9.2% on a year-over-year basis. During the same quarter last year, the firm posted $2.95 earnings per share.
JAZZ has been the subject of a number of recent analyst reports. Oppenheimer set a $180.00 price target on shares of Jazz Pharmaceuticals and gave the stock a “buy” rating in a research report on Sunday, December 23rd. Cantor Fitzgerald reissued a “buy” rating and set a $185.00 price target on shares of Jazz Pharmaceuticals in a research report on Tuesday, February 12th. Wells Fargo & Co reissued a “buy” rating on shares of Jazz Pharmaceuticals in a research report on Sunday, December 23rd. BidaskClub raised shares of Jazz Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday, December 18th. Finally, Wolfe Research initiated coverage on shares of Jazz Pharmaceuticals in a research report on Friday, December 14th. They set a “peer perform” rating for the company. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and thirteen have assigned a buy rating to the company. Jazz Pharmaceuticals currently has a consensus rating of “Buy” and a consensus target price of $188.56.
In other Jazz Pharmaceuticals news, SVP Paul Treacy sold 874 shares of Jazz Pharmaceuticals stock in a transaction on Friday, March 1st. The shares were sold at an average price of $139.50, for a total value of $121,923.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Suzanne Sawochka Hooper sold 3,334 shares of Jazz Pharmaceuticals stock in a transaction on Friday, December 14th. The stock was sold at an average price of $140.21, for a total transaction of $467,460.14. The disclosure for this sale can be found here. In the last ninety days, insiders sold 15,002 shares of company stock valued at $2,074,027. 3.90% of the stock is currently owned by corporate insiders.
Institutional investors have recently added to or reduced their stakes in the business. Enlightenment Research LLC acquired a new position in Jazz Pharmaceuticals in the fourth quarter worth $37,000. First Hawaiian Bank boosted its holdings in Jazz Pharmaceuticals by 42.2% in the fourth quarter. First Hawaiian Bank now owns 320 shares of the specialty pharmaceutical company’s stock worth $39,000 after purchasing an additional 95 shares during the period. Legacy Financial Advisors Inc. acquired a new position in Jazz Pharmaceuticals in the fourth quarter worth $56,000. Stratos Wealth Partners LTD. acquired a new position in shares of Jazz Pharmaceuticals during the third quarter valued at $106,000. Finally, Riverhead Capital Management LLC acquired a new position in shares of Jazz Pharmaceuticals during the third quarter valued at $113,000. 91.97% of the stock is owned by hedge funds and other institutional investors.
Shares of JAZZ traded up $0.48 during mid-day trading on Wednesday, reaching $133.00. 575,783 shares of the stock traded hands, compared to its average volume of 710,468. Jazz Pharmaceuticals has a 12-month low of $113.52 and a 12-month high of $184.00. The company has a quick ratio of 4.16, a current ratio of 4.29 and a debt-to-equity ratio of 0.52. The firm has a market capitalization of $7.99 billion, a P/E ratio of 10.87, a P/E/G ratio of 0.88 and a beta of 1.17.
About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.
Further Reading: Growth Stocks, What They Are, What They Are Not
Get a free copy of the Zacks research report on Jazz Pharmaceuticals (JAZZ)
For more information about research offerings from Zacks Investment Research, visit Zacks.com